Bond.az White LogoBond.az Black Logo

Oppenheimer Cuts Deere Price Target on Brazil Weakness

Oppenheimer cut Deere's price target to $680 from $715, citing Brazil agricultural weakness and tariff impacts, while maintaining an Outperform rating.

William Thomas
ByWilliam Thomas- Senior Editor
|
0

Bond.az - Oppenheimer lowered its price target on Deere & Co. shares (NYSE:DE) to $680 from $715 while maintaining an Outperform rating.

The firm hosted Deere for an investor call to discuss Q2 fiscal 2026 results and factors influencing the second half. Excluding tariff recovery, Q2 performed modestly ahead of expectations.

The second half implies improving price and cost dynamics, easier comparisons, and momentum in construction and forestry offsetting a weaker outlook in Brazil agriculture. Brazil weakness dampened cycle recovery momentum.

Oppenheimer said Deere shares are likely to remain range-bound pending end-of-period updates in late summer. The firm remains confident in Deere's fiscal 2026 trough expectations.

The firm trimmed its estimates and price target while remaining constructive on a modest growth backdrop in 2027.

More News
Today / 11:04
|
827

Evercore ISI Reiterates Amphenol Outperform $180 Target

Evercore ISI reiterates Outperform rating and $180 target on Amphenol. AI revenue could exceed $9 billion by 2026.

0
Today / 11:03
|
415

Okta price target raised to $110 by Cantor

Cantor Fitzgerald raised Okta price target to $110 from $100, citing workforce growth. Stock has 17% upside. Earnings due May 28.

0
Today / 09:33
|
700

Truist Cuts Zscaler Price Target to $200

Truist Securities cuts Zscaler price target to $200, maintains Buy rating. Conservative FY2027 outlook drives stock down 20%.

0
Today / 09:32
|
715

Guggenheim Reiterates Neutral on CrowdStrike Stock

Guggenheim maintains Neutral rating on CrowdStrike (CRWD) citing valuation. Read analysis on stock performance and outlook.

0
Today / 09:01
|
256

Mizuho Starts Century Therapeutics at Outperform

Mizuho initiated coverage on Century Therapeutics with an Outperform rating and $8.00 target, highlighting cell therapy for Type 1 Diabetes.

0
Today / 07:32
|
969

Barclays Upgrades GXO, Raises Price Target to $65

Barclays upgrades GXO Logistics to Overweight, raising price target to $65, citing margin improvement and US expansion.

0
Today / 06:35
|
238

JPMorgan Initiates Larimar at Overweight

JPMorgan starts Larimar Therapeutics at Overweight with $9 target. Stock at $3.47. Key developments on nomlabofusp.

0
Today / 06:02
|
267

Seaport Starts GE Aerospace Coverage with Buy

Seaport Global Securities starts GE Aerospace coverage with a buy rating and $375 price target, citing aftermarket growth potential.

0
Yesterday / 19:30
|
683

Truist Cuts Boston Properties Price Target on Rates

Truist Securities cuts Boston Properties target to $64 from $70, hold rating maintained. Higher rates and capex drive estimate reductions.

0
Yesterday / 12:35
|
248

BayCom Stock Rating Downgraded After Mgmt Changes

DA Davidson downgrades BayCom stock to Neutral after management changes. Find details on price target, dividend, and new leadership.

0
Yesterday / 12:04
|
789

CoreWeave Stock: AI Infrastructure Demand

Deutsche Bank reaffirms Buy rating on CoreWeave amid AI infrastructure demand. Key financials and market insights.

0
Yesterday / 12:03
|
656

Tenable price target raised to $29

Stephens raised Tenable price target to $29, citing platform focus and AI opportunities. Tenable One adoption and new pricing are key catalysts.

0
...